Graeme B. Bolger is founder of BZI Pharma LLC, a pre-clinical stage drug discovery company. The corporate objective of BZI Pharma LLC is to develop and commercialize novel methods for the targeting of drug targets that were previously felt to be "undruggable". The focus of the company's research and development activity is on small molecules with novel and unique properties. Its therapeutic focus is on targets in both cancer and in the central nervous system (CNS), with an emphasis on commercializing agents that address unmet medical needs. Dr. Bolger is a former Associate Professor and a Medical
Oncology Specialist at the University of Alabama at Birmingham, Birmingham, AL, USA. He received his medical degree from McGill University Faculty of Medicine. He was a Resident of Internal Medicine at Johns Hopkins University and a Fellow in Hematology and Medical Oncology at the Memorial Sloan Kettering Cancer Center. He had 42 years of experience in treating patients with cancer. He was awarded America’s Top Doctors for Cancer from 2007 to 2013 and America’s Top Doctors from 2008 to
2014. He has published over 70 publications that span the range from basic studies in molecular genetics and biochemistry to large-scale clinical trials.
Graeme B. Bolger is founder of BZI Pharma LLC, a pre-clinical stage drug discovery company. The corporate objective of BZI Pharma LLC is to develop and commercialize novel methods for the targeting of drug targets that were previously felt to be "undruggable". The focus of the company's research and development activity is on small molecules with novel and unique properties. Its therapeutic focus is on targets in both cancer and in the central nervous system (CNS), with an emphasis on commercializing agents that address unmet medical needs. Dr. Bolger is a former Associate Professor and a Medical
Oncology Specialist at the University of Alabama at Birmingham, Birmingham, AL, USA. He received his medical degree from McGill University Faculty of Medicine. He was a Resident of Internal Medicine at Johns Hopkins University and a Fellow in Hematology and Medical Oncology at the Memorial Sloan Kettering Cancer Center. He had 42 years of experience in treating patients with cancer. He was awarded America’s Top Doctors for Cancer from 2007 to 2013 and America’s Top Doctors from 2008 to
2014. He has published over 70 publications that span the range from basic studies in molecular genetics and biochemistry to large-scale clinical trials.